ALK is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MET status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RET status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [3].